Antibiotic Resistant Infection
Conditions
Keywords
nanoparticles, endodontics infection
Brief summary
Nanoparticles containing antibiotic were prepared and incorporated in in situ gel to treat recurrent endodontic infections
Detailed description
Enterococcus faecalis is the main cause of endodontic infections and form biofilm on dentin, resulting in treatment-resistant periradicular lesions. To overcome these problems, antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction. In this light, Ciprofloxacin hydrochloride (CIP) in chitosan coated PLGA nanoparticles (CIP-CS-PLGA-NPs) and free CIP were embedded in Pluronic® 407/188 to form thermosensitive gels(F1) and (F2) respectively, that were investigated in terms of viscosity, gelation temperature and in-vitro release. The antibacterial efficacy of F1 and F2 were clinically investigated on patients then compared to CIP and Ca(OH)2 pastes by determining bacterial reduction percent and biofilm inhibition assay
Interventions
DRUGCiprofloxacin
studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
Sponsors
British University In Egypt
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Fifty-five patients having single rooted teeth with signs and/or symptoms of post treatment disease that were indicated for non-surgical root canal retreatment were participated in this study
Eligibility
Sex/Gender
ALL
Age
40 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Root canal filled single rooted teeth with post treatment disease manifested by one or more of the following signs and symptoms: * History of recurrent acute and/or chronic periapical abscess * Pain on palpation and/or percussion at least after one month of previous procedure * Radiographic evidence of bone loss either as a new developing lesion or an increase in the size of a pre-existing one.
Exclusion criteria
* Teeth that were badly broken down indicated for extraction or with difficult isolation * Immuno-compromised patients. * Patients with history of taking antibiotics orally. * Periodontally affected teeth.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| controlled release of the drug with associated with infection inhibition | two weeks | drug entrapped in nanoparticles incorporated in in situ gel inhibited the biofilm formation and bacterial recurrent infection |
Countries
Egypt
Outcome results
None listed